Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs.

Autor:	Dembele M; The Research Institute of the McGill University Health Centre, Division of Pediatric Allergy Immunology and Dermatology, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada., Tao S; The Research Institute of the McGill University Health Centre, Division of Pediatric Allergy Immunology and Dermatology, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada., Massoud AH; The Research Institute of the McGill University Health Centre, Division of Pediatric Allergy Immunology and Dermatology, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada., Miah SMS; EpiVax, Inc., Providence, RI, United States., Lelias S; EpiVax, Inc., Providence, RI, United States., De Groot AS; EpiVax, Inc., Providence, RI, United States.; Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA, United States., Mazer BD; The Research Institute of the McGill University Health Centre, Division of Pediatric Allergy Immunology and Dermatology, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2021 Apr 19; Vol. 12, pp. 634509. Date of Electronic Publication: 2021 Apr 19 (Print Publication: 2021).
DOI:	10.3389/fimmu.2021.634509
Abstrakt:	Tregitopes (T regulatory epitopes) are IgG-derived peptides with high affinity to major histocompatibility complex class II (MHCII), that are known to promote tolerance by activating T regulatory cell (Treg) activity. Here we characterized the effect of IgG Tregitopes in a well-established murine model of allergic asthma, demonstrating in vivo antigen-specific tolerance via adoptive transfer of Tregitope-and-allergen-activated Tregs. Asthma is a heterogeneous chronic inflammatory condition affecting the airways and impacting over 300 million individuals worldwide. Treatment is suppressive, and no current therapy addresses immune regulation in severely affected asthmatics. Although high dose intra-venous immunoglobulin (IVIg) is not commonly used in the asthma clinic setting, it has been shown to improve severe asthma in children and in adults. In our laboratory, we previously demonstrated that IVIg abrogates airway hyperresponsiveness (AHR) in a murine model of asthma and induces suppressive antigen-specific T-regulatory cells. We hypothesized that IgG-derived Tregitopes would modulate allergic airway disease by inducing highly suppressive antigen-specific Tregs capable of diminishing T effector cell responses and establishing antigen-specific tolerance. Using ovalbumin (OVA-) and ragweed-driven murine models of allergic airway disease, we characterized the immunoregulatory properties of Tregitopes and performed Treg adoptive transfer to OVA- and ragweed-allergic mice to test for allergen specificity. Treatment with Tregitopes attenuated allergen-induced airway hyperresponsiveness and lung inflammation. We demonstrated that Tregitopes induce highly suppressive allergen-specific Tregs. The tolerogenic action of IgG Tregitopes in our model is very similar to that of IVIg, so we foresee that IgG Tregitopes could potentially replace steroid-based treatment and can offer a synthetic alternative to IVIg in a range of inflammatory and allergic conditions. Competing Interests: AG is a senior officer and shareholder, and SM and SL are employees of EpiVax, Inc., a company specializing in immunoinformatic analysis. EpiVax, Inc. own patents to technologies utilized by associated authors in the research reported here. BM holds research funds from Canadian Institutes for Health Research, National Sciences Engineering and Research Council, The McGill University Health Center Foundation and The Montreal Children’s Hospital Foundation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Dembele, Tao, Massoud, Miah, Lelias, De Groot and Mazer.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu